Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Medicine
Published in: Clinical and Experimental Medicine 3/2007

Open Access 01-09-2007 | Review

New therapies in multiple myeloma

Authors: F. Merchionne, F. Perosa, F. Dammacco

Published in: Clinical and Experimental Medicine | Issue 3/2007

Login to get access

Abstract

The melphalan-prednisone regimen has been considered as standard therapy for patients with multiple myeloma (MM) for many years. Recently, high-dose chemotherapy with stem-cell support has extended progression-free survival and increased overall survival, and it is now considered conventional therapy in younger patients. However, most patients relapse and the salvage treatment is not very effective. New active drugs, including immunomodulatory agents, thalidomide (Thal) and lenalidomide, and the proteasome inhibitor bortezomib, have shown promising anti-myeloma activity. These novel treatments are aimed at overcoming resistance of tumour cells to conventional chemotherapy, acting both directly on myeloma cells and indirectly by blocking the interactions of myeloma cells with their local microenvironment and suppressing growth and survival signals induced by autocrine and paracrine loops in the bone marrow. Thal has been widely studied, mostly in combination regimens in patients with relapsed MM and, more recently, in front-line therapy, showing efficacy in terms of response rate and event-free survival. Bortezomib has been found to possess remarkable activity, especially in combination with other chemotherapeutic agents, in relapsed/refractory and newly diagnosed MM, as well as in patients presenting adverse prognostic factors. Lenalidomide, in combination with dexamethasone, is showing high overall response rates in relapsed and refractory MM and promising results also in first-line therapy. In this paper, the results of the most significant trials with Thal, bortezomib and lenalidomide are reported. Several ongoing clinical studies will hopefully allow the identification of the most active combinations capable of improving survival in patients with MM.
Literature
1.
Riedel DA, Pottern LM (1992) The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 6:225PubMed
2.
3.
Dammacco F, Perosa F, Procaccio P et al (2001) Mieloma multiplo e gammapatie monoclonali: quadri clinici, acquisizioni eziopatogenetiche e progressi terapeutici. Atti 102° Congr Naz Soc Ital Med Int. Annali Italiani di Medicina Interna 16:5s–40s
4.
Attal M, Harousseau JL, Facon T et al (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495–2502PubMedCrossRef
5.
Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883PubMedCrossRef
6.
Chauhan D, Uchiyama H, Akbarali Y et al (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87:1104–1112PubMed
7.
Podar K, Tai YT, Davies FE et al (2001) Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98:428–435PubMedCrossRef
8.
Hideshima T, Chauhan D, Richardson P et al (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277:16639–16647PubMedCrossRef
9.
Yaccoby S, Pearse RN, Johnson CL et al (2002) Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116:278–290PubMedCrossRef
10.
D’Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082–4085PubMedCrossRef
11.
Kenyon BM, Browne F, D’Amato RJ (1997) Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64:971–978PubMedCrossRef
12.
Vacca A, Scavelli C, Montefusco V et al (2005) Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 23:5334–5346PubMedCrossRef
13.
Lentzsch S, LeBlanc R, Podar K et al (2003) Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 17:41–44PubMedCrossRef
14.
Kumar S, Witzig TE, Dispenzieri A et al (2004) Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 18:624–627PubMedCrossRef
15.
Neben K, Moehler T, Kraemer A et al (2001) Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 115:605–608PubMedCrossRef
16.
Hideshima T, Chauhan D, Shima Y et al (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943–2950PubMed
17.
Mitsiades N, Mitsiades CS, Poulaki V et al (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99:4525–4530PubMedCrossRef
18.
Hideshima T, Chauhan D, Schlossman R et al (2001) The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20:4519–4527PubMedCrossRef
19.
Moreira AL, Sampaio EP, Zmuidzinas A et al (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675–1680PubMedCrossRef
20.
Turk BE, Jiang H, Liu JO (1996) Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci U S A 93:7552–7556PubMedCrossRef
21.
Geitz H, Handt S, Zwingenberger K (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31:213–221PubMedCrossRef
22.
Gupta D, Treon SP, Shima Y et al (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15:1950–1961PubMed
23.
Haslett PA, Corral LG, Albert M, Kaplan G (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187:1885–1892PubMedCrossRef
24.
Davies FE, Raje N, Hideshima T et al (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210–216PubMedCrossRef
25.
Mitsiades CS, Mitsiades N, Poulaki V et al (2002) Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21:5673–5683PubMedCrossRef
26.
Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276:22382–22387PubMedCrossRef
27.
Thompson MA, Witzig TE, Kumar S et al (2003) Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br J Haematol 123:305–308PubMedCrossRef
28.
Neben K, Mytilineos J, Moehler TM et al (2002) Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood 100:2263–2265PubMed
29.
Singhal S, Mehta J, Desikan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565–1571PubMedCrossRef
30.
Barlogie B, Desikan R, Eddlemon P et al (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492–494PubMedCrossRef
31.
Yakoub-Agha I, Attal M, Dumontet C et al (2002) Thalidomide in patients with advanced multiple myeloma: a study of 83 patients - report of the Intergroupe Francophone du Myelome (IFM). Hematol J 3:185–192PubMedCrossRef
32.
Palumbo A, Giaccone L, Bertola A et al (2001) Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399–403PubMed
33.
Dimopoulos MA, Zervas K, Kouvatseas G et al (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12:991–995PubMedCrossRef
34.
Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM et al (2004) The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 18:856–863PubMedCrossRef
35.
Kyriakou C, Thomson K, D’sa S et al (2005) Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 129:763–770PubMedCrossRef
36.
Offidani M, Corvatta L, Marconi M et al (2006) Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica 91:133–136PubMed
37.
Tosi P, Zamagni E, Cellini C et al (2002) Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 87:408–414PubMed
38.
Richardson P, Schlossman R, Jagannath S et al (2004) Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 79:875–882PubMedCrossRef
39.
Wu KL, Helgason HH, van der Holt B et al (2005) Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas. Leukemia 19:143–145PubMedCrossRef
40.
Anagnostopoulos A, Weber D, Rankin K et al (2003) Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768–771PubMedCrossRef
41.
Alexanian R, Weber D, Anagnostopoulos A et al (2003) Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 40:3–7PubMedCrossRef
42.
Hussein MA, Baz R, Srkalovic G et al (2006) Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 81:889–895PubMedCrossRef
43.
Rajkumar SV, Hayman S, Gertz MA et al (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319–4323PubMedCrossRef
44.
Cavo M, Zamagni E, Tosi P et al (2004) First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89:826–831PubMed
45.
Alexanian R, Barlogie B, Tucker S (1990) VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33:86–89PubMedCrossRef
46.
Cavo M, Zamagni E, Tosi P et al (2005) Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106:35–39PubMedCrossRef
47.
Barlogie B, Tricot G, Anaissie E et al (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021–1030PubMedCrossRef
48.
Rajkumar SV, Blood E, Vesole D et al (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431–436PubMedCrossRef
49.
Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367:825–831PubMedCrossRef
50.
Dimopoulos MA, Anagnostopoulos A, Terpos E et al (2006) Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica 91:252–254PubMed
51.
Attal M, Harousseau JL, Leyvraz S et al (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108:3289–3294PubMedCrossRef
52.
Brinker BT, Waller EK, Leong T et al (2006) Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer 106:2171–2180PubMedCrossRef
53.
Alexanian R, Weber D, Giralt S, Delasalle K (2002) Consolidation therapy of multiple myeloma with thalidomidedexamethasone after intensive chemotherapy. Ann Oncol 13:1116–1119PubMedCrossRef
54.
Stewart AK, Chen CI, Howson-Jan K et al (2004) Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 10:8170–8176PubMedCrossRef
55.
Adams J, Palombella VJ, Sausville EA et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615–2622PubMed
56.
Hideshima T, Mitsiades C, Akiyama M et al (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101:1530–1534PubMedCrossRef
57.
Rajkumar SV, Richardson PG, Hideshima T, Anderson KC (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630–639PubMedCrossRef
58.
Hideshima T, Richardson P, Chauhan D et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071–3076PubMed
59.
Hideshima T, Chauhan D, Hayashi T et al (2003) Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22:8386–8393PubMedCrossRef
60.
Roccaro AM, Hideshima T, Raje N et al (2006) Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 66:184–191PubMedCrossRef
61.
Shimazaki C, Uchida R, Nakano S et al (2005) High serum bone-specific alkaline phosphatase level after bortezomibcombined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia 19:1102–1103PubMedCrossRef
62.
Heider U, Kaiser M, Muller C et al (2006) Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 77:233–238PubMedCrossRef
63.
Zangari M, Yaccoby S, Cavallo F et al (2006) Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma 7:109–114PubMedCrossRef
64.
Giuliani N, Morandi F, Tagliaferri S et al (2007) The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110:334–338PubMedCrossRef
65.
Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609–2617PubMedCrossRef
66.
Jagannath S, Barlogie B, Berenson J et al (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165–172PubMedCrossRef
67.
Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487–2498PubMedCrossRef
68.
Berenson JR, Yang HH, Sadler K et al (2006) Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 24:937–944PubMedCrossRef
69.
Palumbo A, Ambrosini MT, Benevolo G et al (2007) Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109:2767–2772PubMed
70.
Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib continues to demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: updated results of the APEX trial. Blood (ASH Annual Meeting Abstracts) 106:2547
71.
Jagannath S, Richardson PG, Barlogie B et al (2006) Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 91:929–934PubMed
72.
Popat R, Oakervee HE, Foot N et al (2005) A phase I/II study of bortezomib and low dose intravenous melphalan (BM) for relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts) 106:2555
73.
Davies FE, Wu P, Srikanth M et al (2006) The combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) induces high response rates with minimal toxicity compared to Velcade alone (V) and Velcade plus Dexamethasone. Blood (ASH Annual Meeting Abstracts) 108:3537
74.
Orlowski RZ, Voorhees PM, Garcia RA et al (2005) Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105:3058–3065PubMedCrossRef
75.
Biehn SE, Moore DT, Voorhees PM et al (2007) Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 86:211–216PubMedCrossRef
76.
Orlowski RZ, Zhuang SH, Parekh T et al, the DOXIL-MMY-3001 Study Investigators (2006) The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared with bortezomib alone: results from a planned interim analysis of a randomized phase III study. Blood (ASH Annual Meeting Abstracts) 108:404
77.
Chanan-khan AA, Padmanabhan S, Miller KC et al (2006) Final results of a phase II study of bortezomib (Velcade) in combination with liposomal doxorubicin (Doxi) and thalidomide (VDT) demonstrate a sustained high response rates in patients (pts) with relapsed (rel) or refractory (ref) multiple myeloma. Blood (ASH Annual Meeting Abstracts) 108:3539
78.
Zangari M, Barlogie B, Burns MJ et al (2006) Velcade (V)-Thalidomide (T)-Dexamethasone (D) for advanced and refractory multiple myeloma (MM): long term follow-up of phase I/II trial UARK 2001–37: superior outcome in patients with normal cytogenetics and no prior T. Blood (ASH Annual Meeting Abstracts) 106:2552
79.
Richardson PG, Jagannath S, Avigan DE et al (2006) Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial. Blood (ASH Annual Meeting Abstracts) 108:405
80.
Richardson PG, Chanan-khan AA, Schlossman R et al (2005) A multicenter phase II trial of bortezomib in patients with previously untreated multiple myeloma: efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy. Blood (ASH Annual Meeting Abstracts) 106:2548
81.
Mateos MV, Hernandez JM, Hernandez MT et al (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108:2165–2172PubMedCrossRef
82.
Harousseau JL, Attal M, Leleu X et al (2006) Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 91:1498–1505PubMed
83.
Jagannath S, Durie BG, Wolf J et al (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129:776–783PubMedCrossRef
84.
Harousseau JL, Marit G, Caillot D et al (2006) VEL-CADE/Dexamethasone (Vel/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005–01 randomized multicenter phase III trial. Blood (ASH Annual Meeting Abstracts) 108:56
85.
Oakervee HE, Popat R, Curry N et al (2005) PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129:755–762PubMedCrossRef
86.
Di Carlo BA, Stern JL, Schuster M et al (2006) Breaking the plateau response in myeloma: preliminary results of a phase II pilot study of sequential bortezomib in combination with dexamethasone and pegylated liposomal doxorubicin (DoVeD) in patients no longer responsive to standard induction regimens. Blood (ASH Annual Meeting Abstracts) 108:3538
87.
Orlowski RZ, Peterson BL, Sanford B et al; the Cancer and Leukemia Group B (2006) Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma: Cancer and Leukemia Group B Study 10301. Blood (ASH Annual Meeting Abstracts) 108:797
88.
Hideshima T, Chauhan D, Podar K et al (2001) Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 28:607–612PubMedCrossRef
89.
Dredge K, Marriott JB, Macdonald CD et al (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87:1166–1172PubMedCrossRef
90.
Richardson PG, Schlossman RL, Weller E et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063–3067PubMedCrossRef
91.
Richardson PG, Blood E, Mitsiades CS et al (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108:3458–3464PubMedCrossRef
92.
Baz R, Walker E, Karam MA et al (2006) Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 17:1766–1771PubMedCrossRef
93.
Morgan GJ, Schey SA, Wu P et al (2007) Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 137:268–269PubMedCrossRef
94.
Rajkumar SV, Hayman SR, Lacy MQ et al (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050–4053PubMedCrossRef
95.
Dimopoulos MA, Spencer T, Attal M et al (2005) Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010). Blood (ASH Annual Meeting Abstracts) 106:6
96.
Weber D, Wang M, Chen CI et al (2006) Lenalidomide plus high dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. Blood (ASH Annual Meeting Abstracts) 108:3547
97.
Palumbo A, Falco P, Falcone A et al (2006) Oral Revlimid® plus Melphalan and Prednisone (R-MP) for newly diagnosed multiple myeloma: results of a multicenter phase I/II study. Blood (ASH Annual Meeting Abstracts) 108:800
98.
Chaudhry V, Cornblath DR, Corse A et al (2002) Thalidomide-induce neuropathy. Neurology 59:1872–1875PubMed
99.
Bennett CL, Schumock GT, Desai AA et al (2002) Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med 113:603–606PubMedCrossRef
100.
Cavo M, Zamagni E, Cellini C et al (2002) Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 100:2272–2273PubMedCrossRef
101.
Osman K, Comenzo R, Rajkumar SV (2001) Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344:1951–1952PubMedCrossRef
102.
Mileshkin L, Stark R, Day B et al (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24:4507–4514PubMedCrossRef
103.
Cavaletti G, Beronio A, Reni L et al (2004) Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 62:2291–2293PubMed
104.
Tosi P, Zamagni E, Cellini C et al (2005) Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 74:212–216PubMedCrossRef
105.
Rajkumar SV (2005) Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc 80:1549–1551PubMedCrossRef
106.
Rajkumar SV, Blood E (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354:2079–2080PubMedCrossRef
107.
Dimopoulos MA, Weber D, Chen CI (2005) Evaluating oral lenalidomide (Revlimid) and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica 90[Suppl 2]:160
108.
Palumbo A, Rus C, Zeldis JB et al (2006) Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost 4:1842–1845PubMedCrossRef
109.
Richardson PG, Briemberg H, Jagannath S et al (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113–3120PubMedCrossRef
110.
Lonial S, Waller EK, Richardson PG et al (2005) Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106:3777–3784PubMedCrossRef
Metadata
Title
New therapies in multiple myeloma
Authors
F. Merchionne
F. Perosa
F. Dammacco
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Clinical and Experimental Medicine / Issue 3/2007
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-007-0134-y

Other articles of this Issue 3/2007

Clinical and Experimental Medicine 3/2007 Go to the issue

Original

Combination of the C1429T polymorphism in the G-protein beta-3 subunit gene and the A1330V polymorphism in the low-density lipoprotein receptor-related protein 5 gene is a risk factor for hypercholesterolaemia

Original

Association of gastric cancer with tyrosine hydroxylase gene polymorphism in a northwestern Chinese population

Original

Immunohistochemical investigation of CD34 antigen in male breast carcinoma

Original

Cytogenetic findings and clinical outcomes of adult acute myeloid leukaemia patients

Original

Induction of hepatic haematopoiesis with fibronectin expression by EMT stromal cells during the second trimester of development
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits